Free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia; the ejection fraction by gated cardiac blood flow scan (MUGA) or echocardiogram must be > %
Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > %; for children that are not able to cooperate with multi-gated acquisition (MUGA) and echocardiography, such should be clearly stated in the physicians note
Patient has no significant ischemic heart disease or myocardial infarction (MI) within  months before the first dose of TVB  and currently has adequate cardiac function, as evidenced by a left ventricular ejection fraction (LVEF) of >= % as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); and corrected QT interval (QTc) <  msec on screening electrocardiogram (EKG)
Left ventricular ejection fraction >= %, assessed within  months prior to registration, e.g. by multigated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographic suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal
Left ventricular ejection fraction >= %, assessed within  months prior to study day , e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure
Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= %; for children that are not able to cooperate with multi-gated acquisition scan (MUGA) and echocardiography, such should be clearly stated in the physicians note
History or presence of heart failure or left ventricular dysfunction with ejection fraction < % within the previous  months; if > months cardiac function within normal limits and free of cardiac-related symptoms
Patients must have normal baseline cardiac function based upon echocardiogram or gated blood pool scan (multigated acquisition scan [MUGA]) with an ejection fraction >= %
Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of % or greater, by multiple gated acquisition (MUGA) or echocardiogram; no ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failure
The patient must be free of symptoms of uncontrolled cardiac disease, and must not have compromised cardiac function detected by echocardiogram (ECHO) or by gated cardiac blood flow scan (multi gated acquisition scan [MUGA]) left ventricular ejection fraction [LVEF] > %)
Cardiac: absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= %; for children that are not able to cooperate with multi gated acquisition scan (MUGA) and echocardiography, such should be clearly stated in the physicians note
Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > %; for children not able to cooperate with multigated acquisition (MUGA) or echocardiography, such should be clearly stated in the physicians documentation
Left ventricular ejection fraction ? %, assessed within  months prior to study day , e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure
Significant cardiovascular abnormalities as defined by any one of the following: a. congestive heart failure, b. clinically significant hypotension, c. symptoms of coronary artery disease, d. presence of cardiac arrhythmias on electrocardiography (EKG) requiring drug therapy, e. ejection fraction <  % (echocardiogram or multigated acquisition scan [MUGA]).
Left ventricular systolic dysfunction, defined as ejection fraction below institutional normal by echocardiography or multi-gated acquisition scan (MUGA); or current or past clinical diagnosis of congestive heart failure; history of ejection fraction decreased to below institutional normal or decrease of greater than % attributable to past trastuzumab or pertuzumab therapy
Baseline (<  month before treatment) cardiac left ventricular function with resting ejection fraction of less than % measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogram
Patients must be free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia; the ejection fraction by multi-gated acqusition scan (MUGA) must be > %
Patients must not have symptomatic congestive heart failure, coronary artery disease, cardiomyopathy, or uncontrolled arrhythmias; either an echocardiogram or multi-gated acquisition (MUGA) scan with an ejection fraction >= % must be obtained within  days prior to registration, or within  days prior to registration if the patient has received anthracycline in the  day window; (either method for measuring cardiac function is acceptable; however, the same scan must be used throughout treatment and follow-up to monitor the patient for cardiac toxicity); if the patient has symptoms suggestive of ischemia or congestive heart failure after that cardiac evaluation was done, a repeat study must be obtained prior to registration
Patients must not have symptomatic congestive heart failure, coronary artery disease, cardiomyopathy, or uncontrolled arrhythmias; either an echocardiogram or MUGA scan with an ejection fraction >= % must be obtained within  days prior to registration; (the same scan that was used during induction registration must be used for consolidation registration); the ejection fraction must not have dropped >= % from the baseline ejection fraction; if patient has had symptoms suggestive of ischemia or congestive heart failure after that cardiac evaluation was done, a repeat study must be obtained prior to registration
Left ventricular ejection fraction >= %, assessed within  months prior to study day , e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographic suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal
Subjects with an evaluation of cardiac function indicating normal function on MUGA scan (multiple gated acquisition scan) or other methodology; AND
Have adequate cardiovascular function as defined by: i) a normal B-type natriuretic peptide (BNP) with ii) no signs or symptoms suggestive of cardiac disease and iii) a normal electrocardiogram (ECG); if these criteria are not met, patients must have an echocardiogram or multigated acquisition cardiac scan (MUGA) showing an ejection fraction (EF) of % or greater with no more than \mild\ diastolic dysfunction and a BNP of <  pg/mL to be eligible
Baseline (<  month before treatment) cardiac left ventricular function with resting ejection fraction of less than % measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram
Baseline (<  month before treatment) cardiac left ventricular function with resting ejection fraction of less than % measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogram
Left ventricular ejection fraction >= %, assessed within  months prior to study day , e.g. by multi gated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographical suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal
Cardiac ejection fraction < % on multi gated acquisition scan (MUGA) scan or cardiac echocardiogram (echo) or active symptomatic coronary artery disease; patients with cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consultation as clinically indicated